Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,161 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Embryonal Neoplasm Clear all
Completed Phase 2 Interventional

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

NCT00002535
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, lymphokine-activated killer cells, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, indomethacin
Biological · Drug
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2004
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 23, 2026, 2:08 PM EDT
Recruiting Phase 2 Interventional

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

NCT05465174
View directory record Official record
Conditions
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Interventions
Tovorafenib
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 39 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors

NCT01462396
View directory record Official record
Conditions
Neuroblastoma
Interventions
CD34+ cells selected with the Miltenyi Clinimacs machine
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Months to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 2:08 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04320888
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
172
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

NCT01067066
View directory record Official record
Conditions
Melanoma
Interventions
TPI 287, Temodar (Temozolomide)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 4 Interventional

Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors

NCT00075166
View directory record Official record
Conditions
Brain Neoplasms, Neoplasm Metastasis
Interventions
Stereotactic surgery (SRS), Craniotomy
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

NCT00101166
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Bystander-Based Autologous Tumor Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

NCT02697591
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 23, 2026, 2:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

NCT03474497
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IL-2, Pembrolizumab, Radiotherapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

NCT00096083
View directory record Official record
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 23, 2026, 2:08 PM EDT
Completed No phase listed Observational

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

NCT03199846
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 23, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Study of Panobinostat in Patients With Neuroendocrine Tumors

NCT00985946
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
panobinostat (LBH589)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 23, 2026, 2:08 PM EDT
Completed No phase listed Observational

Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms

NCT03877861
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Readiband Sleep Tracking
Device
Lead sponsor
Allina Health System
Other
Eligibility
22 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 23, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

NCT05168423
View directory record Official record
Conditions
Glioblastoma
Interventions
CART-EGFR-IL13Ra2 Cells
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

NCT01067469
View directory record Official record
Conditions
Brain Cancer, Glioblastoma
Interventions
Standard Dose Bevacizumab, Low Dose Bevacizumab, Lomustine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 23, 2026, 2:08 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069
View directory record Official record
Conditions
Glioblastoma Multiforme, Adult
Interventions
Berubicin, Lomustine
Drug
Lead sponsor
CNS Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
32
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

NCT01665183
View directory record Official record
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 23, 2026, 2:08 PM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

NCT00626405
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
bevacizumab, carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, temozolomide
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
259
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Aurora, Colorado + 163 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

NCT00058370
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, lomustine, vincristine sulfate, adjuvant therapy, iodine I 131 monoclonal antibody 3F8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 23, 2026, 2:08 PM EDT
Not yet recruiting Not applicable Interventional

Hypoxia-targeted Radiotherapy Boost for GBM

NCT07769918
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
Dynamic susceptibility contrast MRI (DSC-MRI), Cercare Medical Neurosuite (CMN) DSC-MRI-derived hypoxia maps, Varian TrueBeam
Device · Other · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

NCT05768880
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood, Refractory Primary Malignant Central Nervous System Neoplasm
Interventions
SC-CAR4BRAIN
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma

NCT04552886
View directory record Official record
Conditions
Glioblastoma
Interventions
TH-1 Dendritic Cell Immunotherapy
Biological
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Camden, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 23, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and EDP1503 in Advanced Melanoma

NCT03595683
View directory record Official record
Conditions
Melanoma (Skin), Melanoma
Interventions
Pembrolizumab, EDP1503
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 23, 2026, 2:08 PM EDT